1. Bernstein, CN, Wajda, A, Svenson, LW, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006; 101: 1559–1568.
Google Scholar | Crossref | Medline | ISI2. Marzano, AV, Borghi, A, Stadnicki, A, et al. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis 2014; 20: 213–227.
Google Scholar | Crossref | Medline | ISI3. Pugliese, D, Guidi, L, Ferraro, PM, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther 2015; 42: 880–888.
Google Scholar | Crossref | Medline4. Denadai, R, Teixeira, FV, Steinwurz, F, et al. Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis 2013; 7: 517–524.
Google Scholar | Crossref | Medline5. Cleynen, I, Van Moerkercke, W, Billiet, T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med 2016; 164: 10–22.
Google Scholar | Crossref | Medline6. Calvet, X, Panés, J, Alfaro, N, et al. Delphi consensus statement: quality indicators for inflammatory bowel disease comprehensive care units. J Crohns Colitis 2014; 8: 240–251.
Google Scholar | Crossref | Medline7. Louis, E, Dotan, I, Ghosh, S, et al. Optimising the inflammatory bowel disease unit to improve quality of care: expert recommendations. J Crohns Colitis 2015; 9: 685–691.
Google Scholar | Crossref | Medline8. Eustace, GJ, Melmed, GY. Therapy for Crohn’s disease: a review of recent developments. Curr Gastroenterol Rep 2018; 20: 19.
Google Scholar | Crossref | Medline9. Goren, I, Barkan, R, Biron, IA, et al. Specialized emergency department assessment and multidisciplinary intervention after discharge improve management of patients with inflammatory bowel diseases. J Clin Gastroenterol. Epub ahead of print 20 January 2021. DOI: 10.1097/MCG.0000000000001490.
Google Scholar | Crossref10. Lee, CK, Melmed, GY. Multidisciplinary team-based approaches to IBD management: how might “one-stop shopping” work for complex IBD care? Am J Gastroenterol 2017; 112: 825–827.
Google Scholar | Crossref | Medline11. Tulchinsky, H, Dotan, I, Alper, A, et al. Comprehensive pouch clinic concept for follow-up of patients after ileal pouch anal anastomosis: report of 3 years’ experience in a tertiary referral center. Inflamm Bowel Dis 2008; 14: 1125–1132.
Google Scholar | Crossref | Medline12. Collamer, AN, Battafarano, DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40: 233–240.
Google Scholar | Crossref | Medline13. Torres, J, Buche, S, Delaporte, E, et al. Skin side effects of inflammatory bowel disease therapy. Inflamm Bowel Dis 2013; 19: 1086–1098.
Google Scholar | Crossref | Medline | ISI14. von Elm, E, Altman, DG, Egger, M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–1457.
Google Scholar | Crossref | Medline | ISI15. Shmidt, E, Wetter, DA, Ferguson, SB, et al. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 2012; 67: e179–e185.
Google Scholar | Crossref | Medline16. Wollina, U, Hansel, G, Koch, A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9: 1–14.
Google Scholar | Crossref | Medline | ISI17. Doyle, LA, Sperling, LC, Baksh, S, et al. Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-alpha therapy: a novel cause of noncicatricial alopecia. Am J Dermatopathol 2011; 33: 161–166.
Google Scholar | Crossref | Medline18. Li, SJ, Perez-Chada, LM, Merola, JF. TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis 2019; 4: 70–80.
Google Scholar | SAGE Journals19. Osorio, F, Magro, F, Lisboa, C, et al. Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature. Dermatology 2012; 225: 163–167.
Google Scholar | Crossref | Medline20. Feagan, BG, Sandborn, WJ, Gasink, C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016; 375: 1946–1960.
Google Scholar | Crossref | Medline | ISI21. Sands, BE, Marano, C. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2019; 381: 1201–1214.
Google Scholar | Crossref | Medline22. Ezzedine, K, Visseaux, L, Cadiot, G, et al. Ustekinumab for skin reactions associated with anti-tumor necrosis factor-α agents in patients with inflammatory bowel diseases: a single-center retrospective study. J Dermatol 2019; 46: 322–327.
Google Scholar | Crossref | Medline23. Matsumoto, S, Mashima, H. Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease. Biologics 2018; 12: 69–73.
Google Scholar | Medline24. Tillack, C, Ehmann, LM, Friedrich, M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014; 63: 567–577.
Google Scholar | Crossref | Medline | ISI25. Feagan, BG, Panés, J, Ferrante, M, et al. Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study. Lancet Gastroenterol Hepatol 2018; 3: 671–680.
Google Scholar | Crossref | Medline26. Sandborn, WJ, Ferrante, M, Bhandari, BR, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology 2020; 158: 537–549.
Google Scholar | Crossref | Medline27. Sands, BE, Chen, J, Feagan, BG, et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: a phase 2a study. Gastroenterology 2017; 153: 77–86.
Google Scholar | Crossref | Medline